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(STAT)Oncostatin M (OSM), a cytokine in the interleukin-6 (IL-6) family, has been proposed to play a protective role in
the central nervous system, such as attenuation of excitotoxicity induced by N-methyl-D-aspartate (NMDA) and
glutamate. However, the potential neuroprotective effects of OSM against mitochondrial dysfunction have never
been reported. In the present study,we tested the hypothesis that OSMmay confer neuronal resistance against 3-
nitropropionic acid (3-NP), a plant toxin that irreversibly inhibits the complex II of the mitochondrial electron
transport chain, and characterized the underlying molecular mechanisms. We found that OSM preconditioning
dose- and time-dependently protected cortical neurons against 3-NP toxicity. OSM stimulated expression ofmy-
eloid cell leukemia-1 (Mcl-1), an anti-apoptotic Bcl-2 family member expressed in differentiating myeloid cells,
that required prior phosphorylation of Janus kinase-1 (JAK1), JAK2, extracellular signal-regulated kinase-1/2
(ERK1/2), signal transducer and activator of transcription-3 (STAT3), STAT1, and cAMP-response element-
binding protein (CREB). Pharmacological inhibitors of JAK1, JAK2, ERK1/2, STAT3, STAT1, and CREB as well as
the siRNA targeting at STAT3 andMcl-1 all abolished OSM-dependent 3-NP resistance. Finally, OSM-dependent
Mcl-1 induction contributed to the enhancements ofmitochondrial bioenergetics including increases in spare re-
spiratory capacity and ATP production. In conclusion, our ﬁndings indicated that OSM induces Mcl-1 expression
via activation of ERK1/2, JAK1/2, STAT1/3, and CREB; furthermore, OSM-mediatedMcl-1 induction contributes to
bioenergetic improvements and neuroprotective effects against 3-NP toxicity in cortical neurons. OSMmay thus
serve as a novel neuroprotective agent against mitochondrial dysfunction commonly associatedwith pathogenic
mechanisms underlying neurodegeneration.
© 2015 Elsevier B.V. All rights reserved.BP, CREB-binding protein; ChIP,
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Oncostatin M (OSM), a cytokine belongs to the interleukin-6 (IL-6)
family, has been shown to play critical roles in inﬂammation, hemato-
poiesis, and cellular proliferation [1,2]. Upon binding to its receptor,
OSM triggers two major signaling cascades: the Janus kinase (JAK)/
Signal transducer and activator of transcription (STAT) and the
mitogen-activated protein kinases (MAPK) pathways [1,2]. Follow-
ing activation of JAKs, predomiantly JAK1 and JAK2, OSMmay induce
STAT1, STAT3, and STAT5 [3]. Moreover, evidence has shown that
phosphorylation of STAT3 at Tyr-705 by JAK2 activates its transcription-
al activity, whereas phosphorylation of Ser-727 by ERK1/2 maximizes
transcriptional ability of STAT3 in a variety of in vitro models [4,5].
Thus, the extents of STAT3 phosphorylation, either at Tyr-705 alone
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may serve as an index for its biological activities.
Myeloid cell leukemia-1 (Mcl-1) was initially identiﬁed as an
immediate-early gene expressed in differentiating myeloid cells [6–8].
Nowadays, it is also known as a regulator for neuronal development
[9]. Mcl-1 contains Bcl-2 homology-1 (BH1), BH2, and BH3 domains,
which are important for apoptosis regulation, as well as a C-terminal
transmembrane domain that targets Mcl-1 to mitochondrial outer
membrane [10]. In addition,Mcl-1 is also involved inmitochondrial ener-
gymetabolisms and ATP production [11]. The N-terminal regions of Mcl-
1 contain two Proline/Glutamic acid/Serine/Threonine (PEST) domains
often found in proteins with rapid turnover rates and, indeed, Mcl-1
has a short half-life that is typically in the range of one to a few hours
[8,12]. The rapid turnover of Mcl-1 is mainly regulated via ubiquitin-
dependent proteasomal degradation [13]. Evidence has demonstrated
that Mcl-1 is highly inducible by a variety of cytokines and growth fac-
tors; the upstream regulatory kinase cascades of Mcl-1 transcription in-
clude MAPKs, phosphatidylinositol-3 (PI3K), and JAK/STAT [7].
In the central nervous system (CNS), major producers of OSM in-
clude microglia, reactive astrocytes, and inﬁltrating leukocytes [14,15].
Several lines of evidence have suggested that OSM may also play a
role in CNS disorders [16,17]. For example, OSM pretreatment may
offer neuroprotective function against excitotoxicity induced by
N-methyl-D-aspartate (NMDA) and glutamate [18,19]. However,
the potential neuroprotective effects of OSM against mitochondrial
dysfunction have never been reported. In the present study, we test-
ed the hypothesis that OSM may confer neuronal resistance against
3-nitropropionic acid (3-NP), a plant toxin that irreversibly inhibits
the complex II of the mitochondrial electron transport chain leading
to energy impairment [20], and characterized the underlyingmolecular
mechanisms. Furthermore, we also investigated whether OSM may
affect the mitochondrial respiratory function and bioenergenics by
measuring the oxygen consumption rate (OCR) in cortical neurons.
2. Materials and methods
2.1. Reagents
3-NP (Cat. No. 73803, Sigma, St. Louis, MO, USA) was dissolved in
phosphate-buffered saline (PBS) as a stock solution of 1M and adjusted
to pH 7.4 with 10 M sodium hydroxide. The 3-NP stock solution was
then dispensed into 1-ml aliquots, protected from light, and stored at
−20 °C until use. Recombinant rat OSM (Cat. No. 400-36, Peprotech,
Rocky Hill, NJ, USA) and cycloheximide (CHX; Cat. No. C7698, Sigma)
were reconstituted in sterile ddH2O to make stock solutions of
100 μg/ml and 20mg/ml before storage at−20 °C and 4 °C, respective-
ly, until use. AG490 (the JAK2/3 inhibitor; Cat. No. 658401, Calbiochem,
La Jolla, CA, USA), ruxolitinib (the JAK1/2 inhibitor; Cat. No. tlrl-rux,
InvivoGen, San Diego, CA, USA), PD98059 (the ERK1/2 inhibitor;
Cat. No. 513000, Calbiochem), stattic (the STAT3 inhibitor; Cat. No.
ab120952, Abcam, Cambridge, MA, USA), SP600125 (the JNK inhibitor;
Cat. No. 420119, Calbiochem), oligomycin (the ATP synthase inhibitor;
Cat. No. sc-201551, Santa Cruz Biotechnology, Inc., Dallas, TX, USA),
and antimycin A (the mitochondrial complex III inhibitor; Cat. No.
A8674, Sigma) were dissolved in dimethyl sulfoxide (DMSO; Cat. No.
JTB-9033-04; Capitol Scientiﬁc, Inc., Austin, TX, USA) as stock solutions
of 10mM, 20mM, 10mM, 50mM, 10mM, 25mM, and 25mM, respec-
tively, before storage at−20 °C. KG501 (CREB inhibitor; Cat. No. 70485,
Sigma) and carbonyl cyanide 4-(triﬂuoromethoxy)phenylhydrazone
(FCCP; the proton ionophore; Cat. No. C2929, Sigma) were both dis-
solved in DMSO as a stock solution of 10 mM and 25 mM, respectively,
and stored at 4 °C until use. S14-95 (STAT1 inhibitor; Cat. No. ALX-350-
299-MC05, Enzo Life Sciences, Inc., Farmingdale, NY, USA) was dis-
solved in methanol as a stock solution of 20 mM and then stored at
−20 °C. Preparation of Aβ25-35 was based on our published paper
[21]. Brieﬂy, Aβ25-35 (Cat. No. A4559, Sigma) was dissolved inautoclaved ddH2O to make a stock solution of 2 mM, dispensed into
aliquots, and immediately stored at−80 °C until use. One day prior to
experimentation, aliquots of Aβ25-35 were incubated at 37 °C for 24 h
to allow aggregation.
2.2. Primary fetal rat cortical cultures
All the procedures for animal care and preparation of fetal rat corti-
cal cultures were carried out humanely in accordance with the guide-
lines described in the “User Manual of Laboratory Animal Center at
National Yang-Ming University”. Primary cortical neurons were
cultured from embryonic day 18 (E18) fetal Sprague-Dawley (SD) rat
brains according to the protocols previously described [22,23]. The cul-
tures were maintained in the neurobasal medium supplemented with
B27 (GIBCO/Invitrogen Corporation) at 37 °C in a humidiﬁed incubator
with 5% CO2. Cortical cells were used for experiments between days-
in-vitro (DIV) 7–9. The cortical culture used in the present study was
a neuron-enriched co-culture system as evidenced by more cells im-
munostained with antibodies recognizing microtubule-associated
protein-2 (MAP-2; approximately 85%) than with glial ﬁbrillary
acidic protein (GFAP; approximately 5–15%), the respective cellular
marker for neurons and astrocytes [22].
2.3. Hoechst staining for cell survival assays
Counting of Hoechst-stained nuclei with normal nuclear morpholo-
gy to quantitatively assess the extent of cell survival was described in
details in our previous publications [24,25]. The “Cell Survival (%)” in
ﬁgures was deﬁned as the mean numbers of surviving cells in experi-
mental groups divided by those of control cultures in the same experi-
ment and then multiplied by 100%.
2.4. Real-time RT-PCR
Extraction of total RNA from cortical cultures, reverse transcription
for cDNA synthesis, and real-time polymerase chain reaction (PCR) for
the detection of Mcl-1 expression at mRNA levels were all performed
as previously described [24]. The primers used in current study were:
5′-CGTAACAAACTGGGGCAGGA-3′ (forward) and 5′-AACCCATCCCAG
CCTCTTTG-3′ (reverse) for Mcl-1; 5′-GCGAGATCCCGCTAACATCA-3′
(forward) and 5′-CTAAGCAGTTGGTGGTGCAG-3′ (reverse) for glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH). Primer pairs had been
blasted to avoid annealing to non-speciﬁc sequences during ampliﬁca-
tion. After cycling, a melting curve was produced by slow denaturation
of the PCR end-products to validate the speciﬁcity of ampliﬁcation.
GAPDHwas included to serve as an internal reference for normalization
of ampliﬁcation efﬁciency.
2.5. Western blotting
The following rabbit antibodies from Cell Signaling Technology
(Danvers, MA, USA) were used: p-STAT3 at Tyr-705 (Cat. No. 9131;
1:500), p-STAT3 at Ser-727 (Cat. No. 9134; 1:250), STAT3 (Cat. No.
12640; 1:1000), p-STAT1 at Tyr-701 (Cat. No. 7649; 1:500), STAT1
(Cat. No. 9172; 1:500), p-JAK2 at Tyr-1007/1008 (Cat. No. 3776;
1:500), JAK2 (Cat. No. 3230; 1:500), p-JAK1 at Tyr-1022/1023 (Cat.
No. 3331; 1:250), ERK1/2 (Cat. No. 4695; 1:500), p-Akt at Ser-473
(Cat. No. 4060; 1:1000), Akt (Cat. No. 4691; 1:1000), p-JNK at Thr-
183/185 (Cat. No. 9251; 1:1000), JNK (Cat. No. 9252; 1:1000), p-CREB
at Ser-133 (Cat. No. 9198; 1:500), CREB (Cat. No. 4820; 1:500), cleaved
caspase-3 (Cat. No. 9664; 1:500), caspase-3 (Cat. No. 9662; 1:1000), and
Bcl-2 (Cat. No. 2870; 1:1000). Additional rabbit antibodies from Abcam
included those against JAK1 (Cat. No. ab133666; 1:500), Mcl-1 (Cat. No.
ab32087; 1:1000), and Bcl-xL (Cat. No. ab32370; 1:500). The mouse
antibodies against β-actin (Cat. No. MAB1501, Millipore, Billerica, MA,
USA; 1:7000), which served as an internal standard for equal loading
Fig. 1.OSMpreconditioningprotects cortical neurons against 3-NP toxicity. (A, B) Rat cortical cultureswere pretreatedwithOSM for 24h at indicated concentrations (A) or 100ng/ml OSM
for indicated times (B) followed by exposure to 2.5mM3-NP or emptymedium for additional 24 h. The extents of cell survival were quantitatively assessed by Hoechst staining. Mean±
S.E.M. from N = 4 in (A) and N = 3 in (B). * and # denote P b 0.05. The “ns” denotes “not signiﬁcant”. (C) Rat cortical cultures were pretreated with 100 ng/ml OSM for 24 h followed
by exposure to 3-NP at indicated concentrations or empty medium for additional 24 h. The extents of cell survival were quantitatively assessed by Hoechst staining. Mean ± S.E.M.
from N = 4. * and # denote P b 0.05. (D) Rat cortical cultures were pretreated with or without 100 ng/ml OSM for 24 h prior to incubation with 2.5 mM 3-NP or in the empty medium
for additional 24 h. Immunocytochemistry combined with Hoechst staining (blue) was then conducted to examine the morphology of mature neurons and astrocytes, using MAP-2
(red) and GFAP (green) as the respective protein marker. Scale bar = 20 μm. Note the signiﬁcantly damaged neuronal morphology by 3-NP (3-NP) that was markedly restored by
OSM preconditioning (OSM+ 3-NP).
2308 S.-H. Chang et al. / Biochimica et Biophysica Acta 1853 (2015) 2306–2325of proteins in each lane, as well as p-ERK1/2 at Thr-202/204 (Cat. No.
9106, Cell Signaling Technology; 1:1000)were also used. The conditions
of hybridization, signal detection, and quantiﬁcation of signal intensities
on the immunoblotswere all performed as previously described [26,27].2.6. Immunocytochemistry and confocal microscopy
The same rabbit antibodies against STAT3 (1:100), p-STAT3 at Ser-
727 (1:50) and Mcl-1 (1:100) for Western blotting were also used for
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(Cat. No. MAB378, 1:150, CHEMICON International, Inc., Temecula, CA,
USA) and the rabbit polyclonal antibody against GFAP (Cat. No. Z0334,
1:600, DakoCytomation Denmark A/S, Denmark) were applied to stain
neurons and astrocytes, respectively. The goat anti-mouse IgG Dylight
594-conjugated secondary antibodies (1:100; excitation: 596 nm/emis-
sion: 617 nm; Cat No. GTX76719, GeneTex, Inc., Irvine, CA, USA) and
goat anti-rabbit IgG HylightFluor 488-labeled secondary antibodies
(1:100; excitation: 499 nm/emission: 523 nm; Cat No. 61056-H488,
AnaSpec, Inc., San Jose, CA, USA) were applied to respectively recognize
the MAP-2 and GFAP primary antibodies. For confocal microscopy, the
coverslips were observed under a laser scanning confocal microscope
(Zeiss LSM700; Oberkochen, Germany) equipped with ﬁlter sets to de-
tect the corresponding ﬂuorescence signals.
2.7. Chromatin immunoprecipitation (ChIP) assay
The ChIP assay was performed using the MangaChIPTM G (Cat.
No. 17-611, Millipore) according to the manufacturer's protocols.
Brieﬂy, primary cortical cultures were washed with 1× PBS and
then crosslinked with 1% paraformaldehyde at room temperature
for 15 min, which was followed by addition of the glycine supplied
in the kit for 5 min. Cells were then washed twice with PBS and
then collected in the PBS with protease inhibitor supplied in the
kit. Following extraction of nuclei, chromatin DNA was shorn by
sonication under the condition of 2-sec pulse-on and 1-sec pulse-
off, processed for a total of 2 min on ice. The same STAT3 antibody
for Western blotting was used in the ChIP assay. Equal amounts of
nuclear proteins (100 μg) were incubated with 20 μl beads and
1 μg rabbit primary antibody against STAT3 or 1 μg normal rabbit
IgG at 4 °C overnight with rotation. Thereafter, the samples were se-
quentially washed by Low-Salt Buffer, High-Salt Buffer, LiCl Buffer,
and TE Buffer for 5 min each on ice with shaking before addition of
Elution Buffer with protease K. Samples were incubated at 62 °C
for 2 h with shaking followed by incubation at 95 °C for 10 min.
The immunoprecipitated DNA was puriﬁed through the Fast-Spin
Column provided in the kit and then subject to PCR for quantiﬁcation.
The sequences of the primers used for ChIP assay were as follows: 5′-
TACTCCTCAGAACCGCGAGA-3′ (forward) and 5′-AGGAGTGAGGAAGG
TTGTGC-3′ (reverse) for the STATx-binding site in theMcl-1 promoter;
5′-AGGATGGGTAGGGAGCTAGG-3′ (forward) and 5′-TGCCAGTGAAAC
CCAATCCT-3′ (reverse) for the non-STATx-binding site in theMcl-1 pro-
moter. PCR was performed in a 10-μl reaction mixture containing 1 μl
eluted DNA samples, primers (ﬁnal concentration at 500 nM each),
and 2× Taq DNA Polymerase Master Mix Red with 1.5 mM MgCl2
(Cat. No. 180303, Ampliqon A/S, Denmark). The following thermocycle
program was used: 95 °C for 5 min followed by 35 cycles of denatur-
ation at 95 °C for 30 sec, annealing at 57 °C for 30 sec, and extension
at 72 °C for 1 min. The PCR products were then analyzed by gelFig. 2.Effects of OSMonMcl-1 expression inprimary cortical neurons. (A) Cortical cultures
were exposed to 100 ng/ml OSM for indicated times before detection of Mcl-1 expression
atmRNA levels by real-time RT-PCR.Mean±S.E.M. fromN=3. * denotes P b 0.05 as com-
paredwith the control cultures. (B, C) Cortical cultureswere exposed to OSM at 100 ng/ml
for indicated times (B) or OSM at indicated concentrations for 24 h (C) before detection of
Mcl-1 proteins by Western blotting. Mean ± S.E.M. from N= 4 in (B) and N= 3 in (C). *
denotes P b 0.05 compared with the corresponding control cultures without OSM expo-
sure. (D) Rat cortical cultures were treated with 100 ng/ml OSM or empty medium for
24 h. This was followed by immunocytochemistry combined with Hoechst staining
(blue) to observe expression of Mcl-1 (green). MAP-2 (red, upper panels) and NeuN
(red, lower panels) were used as protein markers for neuronal dendrites and nucleus, re-
spectively. Scale bar = 10 μm. Note that OSM enhances Mcl-1 expression in the MAP-2-
and NeuN-positive cells, indicative of its neuronal expression. (E) Cells were incubated
with or without 100 ng/ml OSM for 24 h followed by exposure to 10 μg/ml cycloheximide
(CHX) for indicated times before detection ofMcl-1 proteins byWestern blotting. The cal-
culated half-lives (T1/2) of Mcl-1 proteins in the cortical cells with or without exposure to
OSM are shown in the lower panels. Mcl-1 expression levels in the control cultures, which
were treated with neither cycloheximide nor OSM, were set as 100%. Mean± S.E.M. form
N= 3-4. The “ns” denotes “not signiﬁcant”.electrophoresis through 2% agarose gels (Cat. No. UR-AGA001,
UniRegion Bio-Tech, Taipei, Taiwan) in 0.5× TBE buffer (Cat. No. UR-
TBE-002-1 L, UniRegion Bio-Tech).
2.8. Transfection of siRNAs into primary cortical neurons
Transfection of siRNAs for the knockdown of speciﬁc genes in prima-
ry cortical neurons was conducted as previously described [23]. The
Fig. 2 (continued).
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siRNA with scrambled sequences were all purchased from Dharmacon
Inc. (Lafayette, CO, USA). The 4 target sequences for the Mcl-1 Accell
SMARTpool siRNA mixture were as follows (5′ → 3′): CUGUUGACUU
ACUAAAUUG, CCAAUCUGUUUCUGUAUUU, UGAUCAGUUCUAGUGU
AUA, and GCGUAAGUUUAUUAGUCUA; the 4 target sequences for the
STAT3 Accell SMARTpool siRNA mixture were as follows (5′ → 3′):
CUCAUAAACUGAAAGGGUA, CACUCAAAUUCCAAUGUAU, CCAGUAUG
CUUGUCUGUUG, and GUAUGGUCCUUAUUCUAUG. A non-targetingAccell siRNA (D-001910-01) was used as the negative control in all
the siRNA transfection experiments.
2.9. Measurement of cellular oxygen consumption
To determine the cellular bioenergetics, the oxygen consumption
rate (OCR) was measured by a XF24 Extracellular Flux Analyzer
(Seahorse Bioscience, Billerica, MA) [28–31]. Primary cortical cultures
were seeded at a density of 60,000 cells per well on Seahorse XF-24
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quent to experimental manipulations, the culture mediumwas replaced
with pre-warmed DMEM medium (Cat. No. 12800, Life technology;
DMEM base medium supplemented with 25 mM glucose, 1 mM sodium
pyruvate, 110 mM NaCl, 4 mM L-glutamine, pH 7.4) and incubated at
37 °C in a non-CO2 incubator for 1 h before the extracellular ﬂux analysisFig. 3.Mcl-1 induction mediates the neuroprotective effects of OSM against 3-NP toxicity.
(A) Primary cortical cells were transfected with 0.1 μM Mcl-1 (Mcl-1) siRNA or 0.1 μM
scrambled (sc) siRNA for 72 h during DIV 4-7. This was followed by exposure to
100 ng/ml OSM for additional 24 h before detection of Mcl-1 expression. Mean ± S.E.M.
from N = 3. *, #, and § all denote P b 0.05. (B) Cortical cultures were transfected with
0.1 μMMcl-1 siRNA or sc siRNA for 72 h during DIV 4–7. This was followed by treatment
with or without 100 ng/ml OSM for 24 h and exposure to 2.5mM3-NP or emptymedium
for additional 24 h. Hoechst stainingwas conducted to determine the extents of cell surviv-
al. Mean ± S.E.M. from N= 3. * and # denote P b 0.05. The “ns” denotes “not signiﬁcant”.
(C) Rat cortical cultures were incubated in 100 ng/ml OSM for 24 h followed by exposure
to 2.5 mM 3-NP or empty medium for additional 8 h before detection of Mcl-1. Mean ±
S.E.M. from N= 4. * and # denote P b 0.05. The “ns” denotes “not signiﬁcant”.[28]. Mitochondrial functionwas quantitatively assessedwith sequential
injections of oligomycin (the ATP synthase inhibitor), FCCP (the proton
ionophore), and antimycin A (the mitochondrial complex III inhibitor),
each was diluted in pre-warmed DMEMmediumwith the ﬁnal concen-
tration at 1 μM. Four baseline measurements of OCR were determined
before injection of mitochondrial inhibitors, and three OCR readings
were recorded after addition of each of the above inhibitors. The param-
eters as indices of mitochondrial function were automatically recorded
and calculated by the Seahorse XF-24 software.
2.10. Statistical analysis
Results are expressed as Mean ± S.E.M. from the sample numbers
(N). For counting of Hoechst-stained surviving cells, the N represents
data collected from one independent experiment using one cortical cul-
ture. Each independent experiment contained 3 coverslips for every
experimental condition. On each coverslip, 3–4 vision ﬁelds were ran-
domly selected for counting to obtain the average numbers of surviving
cells in each vision ﬁeld. The mean numbers of surviving cells for each
independent experimentwere therefore derived from a total of 9–12 vi-
sion ﬁelds out of 3 coverslips for the same experimental condition. For
Western blotting, real-time RT-PCR, and ChIP assay showing quantita-
tive results, each N represents data collected from one experiment
using one culture; combined data from at least 3 independent using 3
different cultures are shown. For all the double immunoﬂuorescence
staining (Figs. 1C, 2D, 5C, 6G, 7F, 8E), representative images from3 inde-
pendent experiments using 3 different cultures are shown. For quantita-
tive determination of OCR without prior siRNA transfection (Fig. 9B–F),
combined results derived from 10 (control) and 12 (OSM) measure-
ments out of 4 different cultures are shown. In Fig. 9G and H, combined
results from 5–7 measurements out of 3 different cultures for each
experimental condition are shown. Multiple groups were analyzed
by one-way analysis of variance (ANOVA) followed by a post-hoc
Student-Newman-Keuls test; two groups were analyzed by Student's
t-test. P-values of less than 0.05 were considered signiﬁcant.
3. Results
3.1. Neuroprotective effects of OSM preconditioning against 3-NP toxicity
We ﬁrst tested whether OSM may afford neuroprotection against
mitochondrial inhibition induced by 3-NP. Our results indicated that
pretreatment of cortical cultures with OSM at 25–100 ng/ml for 24 h re-
sulted in concentration-dependent cytoprotective effects against 3-NP
at 2.5 mM [32]; the optimal protective effect of OSM was observed at
100 ng/ml (Fig. 1A). At this dosage, OSM also conferred 3-NP resistance
to cortical cells time-dependently, exhibiting the maximal efﬁcacy after
24 h of preconditioning (Fig. 1B). We then further tested the protective
effects of OSM preconditioning against 3-NP at lower concentrations.
Results indicated that 3-NP at 0.5–2.5 mM exerted dose-dependent cy-
totoxicity towards cortical cultures; OSM preconditioning for 24 h also
showed the tendency of cytoprotection against 3-NP at 1.5 mM, albeit
achieving a marginal statistical signiﬁcance at P = 0.051 (Fig. 1C). Pos-
sibly due to weaker cytotoxic potency of 3-NP at 0.5mM, the protective
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(Fig. 1C). In addition to quantitative assessment for cell survival by
Hoechst staining, confocal microscopy also revealed OSM-dependent
restoration of neuronal morphology from the 3-NP-induced injuries
(Fig. 1D). Based on these ﬁndings, preconditioning of cortical cultures
with 100 ng/ml OSM for 24 h followed by exposure to 3-NP at 2.5 mM
for additional 24 h was selected as the main experimental paradigm
for most of the subsequent experiments.
In addition to 3-NP that directly inhibit mitochondrial function, we
also tested whether the observed protective effects of OSM precondi-
tioning can be extended to other types of neurotoxins. Amyloid beta-
peptide (Aβ) is the major neurotoxic component in the senile plaquesFig. 4. Involvements of JAK1/2 and ERK1/2 in the OSM-dependent Mcl-1 induction and neurop
before detection of phosphor-JAK2 at Try-1007/1008 and JAK2 (A), phosphor-JAK1 at Tyr-1022
from N=3 in (A), N=3 in (B), andN=4 in (C). * denotes P b 0.05 compared with the corresp
without 50 μMPD98059 or 50 μMAG490 for 24 h before detection ofMcl-1.Mean± S.E.M. from
ruxolitinib or the same amount of the solventDMSO for 24 h before detection ofMcl-1.Mean±
rat cortical cultures were exposed to 100 ng/ml OSM alongwith 50 μMPD98059 (F), 50 μMAG4
these pharmacological inhibitors. After OSMpreconditioningwith orwithout inhibitors, cortica
24 h before Hoechst staining to determine the extents of cell survival. Mean ± S.E.M. from N=observed in the brains of Alzheimer's disease (AD) patients [33,34].
The synthetic Aβ25–35 is also known to cause mitochondrial dysfunc-
tion [35]. We therefore also explored potential cytoprotective actions
of OSM against Aβ25–35. Results indicated that OSM preconditioning
for 24 h signiﬁcantly, albeit partially, protected cortical cultures against
Aβ25–35 toxicity (Supplementary Fig. 1A). Thus, OSM-mediated pro-
tective effect is not restricted to the complex II inhibitor 3-NP; rather,
it can also be applied to other neurotoxic insults capable of inducingmi-
tochondrial inhibition, like Aβ. However, Mcl-1 siRNA failed to suppress
the OSM-dependent cytoprotection against Aβ25–35, suggesting in-
volvements of additional factors other than Mcl-1 (Supplementary
Fig. 1B).rotection. (A-C) Rat cortical cultures were exposed to 100 ng/ml OSM for indicated times
/1023 and JAK1 (B), or phosphor-ERK1/2 at Thr-202/204 and ERK1/2 (C). Mean ± S.E.M.
onding control cultures. (D) Rat cortical cultures were exposed to 100 ng/ml OSMwith or
N=5. * and # denote P b 0.05. (E) Cultureswere exposed to 100 ng/ml OSMwith 0.5 μM
S.E.M. fromN=3. * and#denote P b 0.05. The “ns”denotes “not signiﬁcant”. (F-H) Primary
90 (G), or 0.5 μMruxolitinib (H) for 24 h; the solvent DMSO served as negative controls for
l cultureswere challengedwith 2.5mM3-NP or incubated in emptymedium for additional
3 in (F), (G), and (H). * and # denote P b 0.05. The “ns” denotes “not signiﬁcant”.
Fig. 4 (continued).
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To identify the key protective mediators downstream of OSM, we
ﬁrst examined the expression patterns of several anti-apoptotic pro-
teins following OSM treatment. Results indicated that, during an epi-
sode of 24-h exposure, OSM at 100 ng/ml failed to alter the expression
levels of Bcl-2 (Supplementary Fig. 2A) and Bcl-xL (Supplementary
Fig. 2B) in rat cortical cultures. In addition, OSMpretreatment also failed
to alter the extents of caspase-3 cleavage in cortical cultures exposed to
3-NP (Supplementary Fig. 2C). Despite lack of evidence linking OSM di-
rectly to the induction ofMcl-1, DNAmicroarray analysis has previously
revealed that OSMmodulates the expression of Mcl-1, along with other
Bcl-2 family members including Bax, Bad, Bnip3, and Bcl-2, in osteosar-
coma cells [36]. Further, OSM belongs to the IL-6 family, whereas Mcl-1
is known to be regulated by IL-6 in humanmyeloma cells [37,38]. There-
fore, we determined whether OSM may affect the expression proﬁle of
Mcl-1 in cortical neurons. Results showed that OSM exposure signiﬁ-
cantly increased expression of Mcl-1 at mRNA levels, beginning at 2 h
and lasted until 24 h (Fig. 2A). Thus, expression ofMcl-1mRNA is sub-
ject to transcriptional regulation by OSM.We then analyzed the expres-
sion pattern of Mcl-1 proteins. OSM treatment time-dependently
increased Mcl-1 expression, reaching approximately 2 folds of the con-
trol level after 24 h (Fig. 2B). After an episode of 24-h exposure, OSM at
5-200 ng/ml also dose-dependently enhanced the expression of Mcl-1,
achieving the maximal extent at 100 ng/ml (Fig. 2C).
Considering our cortical cultures are a neuron-enriched co-culture
system containing both neurons and astrocytes [22], we furtheridentiﬁed the cell types expressing Mcl-1 upon OSM stimulation. Dou-
ble immunoﬂuorescence staining, usingMAP-2 andNeuN as the respec-
tive marker of neuronal dendrites and nucleus, revealed that Mcl-1
expression in the cytoplasm of the MAP-2- and NeuN-positive cells
was enhanced after 24-h exposure to OSM (Fig. 2D), indicative of neu-
ronal expression of this protein upon OSM stimulation.
Mcl-1 is known to have a short half-life [10]. Therefore, in addition to
transcriptional regulation we also examined whether OSM may affect
the protein stability of Mcl-1. Using the protein synthesis inhibitor cy-
cloheximide, we found that the half-lives of Mcl-1 with and without
OSM treatment were approximately 1.48 h and 1.86 h, respectively;
however, statistical signiﬁcance of the difference was not achieved
(Fig. 2E). Therefore, OSM does not modulate Mcl-1 stability, suggesting
that transcriptional regulation may be the prime mechanism by which
OSM increases the expression level of Mcl-1 in rat cortical neurons.
3.3. Critical role of OSM-inducedMcl-1 in its neuroprotective effects against
3-NP
Despite its roles as an anti-apoptotic protein possessing beneﬁcial
function, whether Mcl-1 mediates the neuroprotective effects of
OSM against 3-NP-induced mitochondrial dysfunction remained to be
clariﬁed. To address this issue, we determined the effects ofMcl-1 knock-
down on OSM-dependent 3-NP resistance in cortical neurons. We ﬁrst
conﬁrmed that the siRNA targeting atMcl-1 gene, but not the negative
control siRNA with scrambled sequences, effectively suppressed its ex-
pression induced by OSM (Fig. 3A). Consistently, knockdown of Mcl-1
2314 S.-H. Chang et al. / Biochimica et Biophysica Acta 1853 (2015) 2306–2325by siRNA also completely abolished OSM-dependent 3-NP resistance
without affecting cell survival when the cortical cells were exposed to ei-
ther OSM or 3-NP alone (Fig. 3B). In addition to Mcl-1 induction by OSM
alone, we also explored the combined effects of OSM and 3-NP on the ex-
pression level of Mcl-1. Results revealed that Mcl-1 induction by OSM
pretreatment for 24 h lasted until at least 8 h after removal of this cyto-
kine (OSM; Fig. 3C); challengewith 3-NP alone for 8 hwithout prior ex-
posure to OSM (3-NP) signiﬁcantly decreased Mcl-1 expression as
compared with both control (Ctrl) or OSM-treated (OSM) cultures
(Fig. 3C). Interestingly, OSM preconditioning for 24 h maintained
the expression level of Mcl-1, at least to the extent of control culture,
despite subsequent 3-NP exposure for 8 h (OSM + 3-NP; Fig. 3C).Fig. 5. Effects of OSM on STAT3 phosphorylation, nuclear translocation, and protein expression.
detection of phosphor-STAT3 at Tyr-705 or Ser-727 as well as total STAT3. Mean± S.E.M. from
cultures. (C) Rat cortical cultures were treated with 100 ng/ml OSM or empty medium for 16
observe expression of speciﬁc proteins: STAT3 (green) and MAP-2 (red) in the upper panels a
panels: scale bar = 5 μm; lower panels: scale bar = 10 μm. (D) Cortical cultures were expos
μM for 15 min. This was followed by detection of phosphor-STAT3 at Tyr-705 or Ser-727 as w
cultures are shown. Note that AG490 partially blocked STAT3 phosphorylation at Tyr-705, wh
were exposed to 100 ng/ml OSMwith or without 0.5 μM ruxolitinib for 15min before detection
experiments using 3 different cultures are shown.Note that ruxolitinib completely blocked STAT
indicated times before detection of total STAT3 byWestern analysis. Mean ± S.E.M. from N=These ﬁndings together indicated that OSM preconditioning pre-
vents declined Mcl-1 expression caused by 3-NP, thereby maintain-
ing the basal level of this protein. Together with the above results
using siRNA-mediated knockdown, our ﬁndings indicated that such
maintenance of cellular Mcl-1 levels by OSM preconditioning is crit-
ical for the observed 3-NP resistance in rat cortical neurons.
3.4. JAK1, JAK2, and ERK1/2 are involved in OSM-mediated Mcl-1 induction
and neuroprotection
Since robust evidence has shown that JAK/STAT and MAPK are
the two major signaling cascades triggered by OSM [1,2], we ﬁrst(A, B) Primary cortical cultureswere exposed to 100 ng/ml OSM for indicated times before
N= 3-4 in both (A) and (B). * denotes P b 0.05 compared with the corresponding control
h. This was followed by immunocytochemistry combined with Hoechst staining (blue) to
s well as phosphor-STAT3 at Ser-727 (green) and NeuN (red) in the lower panels. Upper
ed to 100 ng/ml OSM with or without PD98059 or AG490 at indicated concentrations in
ell as total STAT3. Representative blots from 2 independent experiments using 2 different
ereas PD98059 in part inhibited STAT3 phosphorylation at Ser-727. (E) Cortical cultures
of phosphor-STAT3 at Tyr-705 and total STAT3. Representative blots from 3 independent
3 phosphorylation at Tyr-705. (F) Rat cortical cultureswere exposed to 100 ng/ml OSM for
3. * denotes P b 0.05 compared with controls.
Fig. 5 (continued).
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JAK1, and ERK1/2 in cortical cultures. We found that JAK2 was phos-
phorylated after 5min of OSM exposure; JAK2 phosphorylation reached
approximately 1.5 folds as compared to the controls at 15 min and
returned to basal level after 60-min exposure to OSM (Fig. 4A). In addi-
tion, a transient increase of JAK1 phosphorylation was observed after
5 min of OSM exposure, reaching the maximal extent at approximately
25 folds at 15min and rapidly declined thereafter at 60min (Fig. 4B). Inaddition to JAK1 and JAK2, ERK1/2 was also phosphorylated after 5 min
of OSM exposure and this ERK1/2 phosphorylation lasted until 60 min
(Fig. 4C). These above results indicated rapid phosphorylation, and
hence activation, of JAK1, JAK2, and ERK1/2 within 5 min following ex-
posure to OSM. However, transient phosphorylation of these kinases
does not causally support their crucial roles in mediating the observed
Mcl-1 induction and neuroprotection of OSM. Pharmacological studies
using the JAK2/3 inhibitor AG490, the ERK1/2 inhibitor PD98059, and
Fig. 6. Roles of STAT3 on OSM-inducedMcl-1 expression and neuroprotection. (A) A diagram showing the promoter region ofMcl-1 gene, which includes the predicted binding sites of STATx
and CREB as well as the positions of the PCR primers used in the ChIP assay. (B) Primary rat cortical cultures were treated with 100 ng/ml OSM or emptymedium for 1 h and 16 h before ChIP
assays. Immunoprecipitationwas conducted using 1 μg STAT3 antibody as described inMaterials andmethods. The same amount of normal rabbit IgG served as the negative control for immu-
noprecipitation. For PCR reactions, two sets of primerswere designed; onewas employed to amplify the sequence containing the predicted STATx-binding site and another for the non-STATx-
binding site. PCR reactions using the genomic DNAwithout prior immunoprecipitation as the template and the primer pair designed for non-STATx-binding sitewere conducted to serve as the
positive control (PC).Mean±S.E.M. fromN=3. * denotes P b 0.05 comparedwith the corresponding control cultures. (C) Rat cortical cultureswere exposed to 100ng/ml OSMwith orwithout
5 μMstattic, the STAT3 inhibitor, for 24 h before detection ofMcl-1.Mean±S.E.M. fromN=3. * and # denote P b 0.05. The “ns” denotes “not signiﬁcant”. (D) Primary rat cortical cultureswere
transfectedwith0.1 μMSTAT3 (STAT3) siRNAor scrambled (sc) siRNA for 72 hduringDIV4-7. Thiswas followedby exposure to 100ng/mlOSM for additional 24hbefore detection of phosphor-
STAT3 at Tyr-705 or Ser-727 as well as total STAT3. Representative immunoblots are shown in the upper left panel. Relative expression levels of total STAT3 normalized to β-actin are shown in
the bar graph of upper right panel. The cellular contents of phosphor-STAT3 at Tyr-705, also normalized to β-actin, are shown in the bar graph of lower left panel. The extents of STAT3 phos-
phorylation at Tyr-705 that were normalized to total STAT3 are shown in the bar graph of lower right panel. Mean± S.E.M. from N=3-4. *, #, and § all denote P b 0.05. The “ns” denotes “not
signiﬁcant”. (E) Primary rat cortical cultureswere transfectedwith0.1 μMSTAT3 (STAT3) siRNAor scrambled (sc) siRNAor 72hduringDIV4-7. Thiswas followedbyexposure to100ng/mlOSM
for 24hbefore detectionofMcl-1.Mean±S.E.M. fromN=3. *, #, and § all denote Pb 0.05. (F) The transfection conditions for siRNAswere the sameas described above in (E). At the completion
of transfection, cortical cultures were treated with or without 100 ng/ml OSM for 24 h followed by exposure to 2.5 mM 3-NP or emptymedium for additional 24 h. Hoechst staining was then
conducted to determine the extents of cell survival. Mean± S.E.M. from N=3. *, #, and § all denote P b 0.05. (G) The experimental conditions were identical to (F) except that immunocyto-
chemistry combined with Hoechst staining (blue) were conducted to observe the morphology of mature neurons and astrocytes. MAP-2 (red) and GFAP (green) were used as the respective
protein marker for mature neuronal dendrites and astrocytes. Scale bar = 20 μm. Note that the STAT3 siRNA effectively neutralized OSM-mediated 3-NP resistance.
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2318 S.-H. Chang et al. / Biochimica et Biophysica Acta 1853 (2015) 2306–2325the JAK1/2 inhibitor ruxolitinib were therefore conducted. As a result,
partial inhibition of OSM-induced Mcl-1 expression by both AG490
and PD98059 was noted (Fig. 4D), whereas ruxolitinib completely
abrogated OSM-mediated Mcl-1 induction (Fig. 4E). Further,
coincubation of OSM with PD98059 (Fig. 4F), AG490 (Fig. 4G), or
ruxolitinib (Fig. 4H) during the preconditioning phase all signiﬁcant-
ly abolished OSM-dependent neuroprotective effects against 3-NP.
Together, results shown in Fig. 4 revealed critical involvements ofJAK1, JAK2, and ERK1/2 in mediating OSM-induced Mcl-1 expression
and 3-NP resistance.
In addition to JAK1, JAK2, and ERK1/2, we also investigated possible
involvements of other kinases including Akt and JNK. Our results indi-
cated that OSM did not signiﬁcantly affect the phosphorylation status
of Akt (Supplementary Fig. 2A) and JNK (Supplementary Fig. 2B); fur-
thermore, the JNK inhibitor SP600125 at 20 μM failed to inhibit OSM-
induced Mcl-1 expression (Supplementary Fig. 2C). These ﬁndings
2319S.-H. Chang et al. / Biochimica et Biophysica Acta 1853 (2015) 2306–2325further strengthened the speciﬁcity of JAK1, JAK2, and ERK1/2 in con-
tributing to OSM-dependent Mcl-1 induction and neuroprotection.
3.5. JAK/ERK-dependent phosphorylation of STAT3 and induction of STAT3
protein by OSM
Next, we examined the potential OSM effects on the phosphoryla-
tion status of STAT3, awell-established transcription factor downstream
of JAKs. Robust evidence has shown that biological activities of STAT3
are attributable to its phosphorylation, either at Tyr-705 by JAK2 or
at Ser-727 by ERK1/2 [4,5]. Our results revealed that short-term
(0–60 min; Fig. 5A) as well as long-term (0–24 h; Fig. 5B) exposure to
OSM time-dependently increased the extents of STAT3 phosphorylation
at both Tyr-705 and Ser-727. OSM treatment for 5 min induced phos-
phorylation of STAT3 at Tyr-705, achieving themaximal level at 4 h (ap-
proximately 20 folds of the control level) and lasted until 24 h (Fig. 5A
and B). For the phosphorylated STAT3 at Ser-727, similar results were
observed, albeit to a much lesser extent as compared to Tyr-705 phos-
phorylation (approximately 2 folds of the control level; Fig. 5A, B). Phos-
phorylation of STAT3 is expected to result in nuclear translocation to
activate the expression of its target genes. Double immunoﬂuorescence
staining revealed that OSM treatment enhanced the nuclear contents of
total STAT3 and the phosphor-STAT3 at Ser-727 in the MAP-2- and
NeuN-positive cells, respectively (Fig. 5C), indicating nuclear localiza-
tion of STAT3 in neurons upon OSM stimulation.
To elucidate the correlations between JAK1/JAK2/ERK1/2 and the
phosphorylation status of Tyr-705/Ser-727 in STAT3, cortical cultures
were exposed to OSM for 15 min along with the pharmacological inhib-
itors each targeting at a speciﬁc kinase. Results showed partial suppres-
sion of STAT3 phosphorylation at Tyr-705 by 200 μM and 250 μM
AG490, the JAK2/3 inhibitor, whereas STAT3 phosphorylation at Ser-
727 was signiﬁcantly abolished by 150 μM PD98059, the ERK1/2 inhibi-
tor (Fig. 5D). Notably, STAT3 phosphorylation at Tyr-705was completely
abolished by the JAK1/2 inhibitor ruxolitinib (Fig. 5E). Thus, JAK1 and
JAK2 participate in STAT3 phosphorylation at Tyr-705, while ERK1/2 is
involved in STAT3 phosphorylation at Ser-727 (Fig. 5D, E). In addition
to the OSM effects on STAT3 phosphorylation, we found that the expres-
sion level of total STAT3was also increased after 16-h and 24-h exposure
to OSM (Fig. 5F). Thus, OSM regulates STAT3 activity via at least two dis-
tinctmechanisms, namely enhancing its phosphorylation at Tyr-705 and
Ser-727 via activation of JAK1, JAK2, and ERK1/2 as well as increasing
total cellular contents of STAT3 proteins.
3.6. STAT3 directly participates in OSM-dependent Mcl-1 induction and
neuroprotection
To further explore whether STAT3 directly binds to the promoter re-
gion ofMcl-1 gene upon OSM exposure, ChIP assay was conducted. The
predicted binding sites for STATs and the positions of primer pairs used
in ChIP assays are depicted in Fig. 6A. Results indicated that OSM expo-
sure for 1 h and16h both enhanced STAT3binding to theMcl-1 promot-
er (Fig. 6B). To rule out any potential false-positive signal, one pair ofFig. 7. Roles of STAT1 in OSM-induced Mcl-1 expression and neuroprotection. (A) Primary cort
long-term: 0–24 h) before detection of phosphor-STAT1 at Tyr-701 and total STAT1. Quantitati
60 min) are shown in the bar graph. Mean ± S.E.M. from N= 3. * denotes P b 0.05 as compa
PD98059 or AG490 at indicated concentrations in μM for 15 min before detection of phosphor-
using 2 different cultures are shown. Note that phosphorylation of STAT1 at Tyr-701 was abolis
with or without 0.5 μM ruxolitinib for 15 min before detection of phosphor-STAT1 at Tyr-701
cultures are shown. Note that ruxolitinib completely abolished OSM-induced STAT1 pho
20 μM S14-95, the STAT1 inhibitor, or the same amount of methanol, its solvent, for 24 h before
“not signiﬁcant”. (E, F) Primary rat cortical cultures were treated with 100 ng/ml OSMwith 20
medium for additional 24 h. In (E), cells were subject to Hoechst staining to determine the ext
munocytochemistry combined with Hoechst staining (blue) were conducted to observe the m
the respective protein marker for mature neuronal dendrites and astrocytes. Scale bar = 20 μ
fragmentation, whereas S14-95 reversed this OSM-dependent neuroprotective effects.primerswas also designed to amplify the DNA sequencewithin the pro-
moter ofMcl-1 that was predicted to be outside the STAT-binding sites.
As expected, no signal can be detected by ChIP assay using this primer
pair amplifying the non-STATx-binding sequence, either with or with-
out OSM treatment for 1 h; this was not due to failure of PCR reaction
as genomicDNAwithout prior immunoprecipitation can be successfully
ampliﬁed (Fig. 6B). Once the OSM-dependent enhancement of STAT3
binding to the Mcl-1 promoter was conﬁrmed, we then characterized
potential involvement of STAT3 in OSM-dependent Mcl-1 induction
and neuroprotection. Stattic is a non-peptide small molecule that can
selectively inhibit STAT3 function by blocking its SH2 domain and
interrupting its dimerization [39]. Results shown in Fig. 6C indicated
that stattic at 5 μM [40,41] completely abolished OSM-induced Mcl-1
expression. For gene-speciﬁc knockdown, we ﬁrst conﬁrmed that
STAT3 siRNA fully suppressed the OSM-induced STAT3 expression
down to the control level, despite the increased total STAT3 proteins
(immunoblots in Fig. 6D). Further, this siRNA also diminished the
amounts of phosphor-STAT3 at both Tyr-705 and Ser-727 (immunoblots
in Fig. 6D). Quantitative analyses of signal intensities on these blots con-
ﬁrmed the efﬁcacy of siRNA in knocking down STAT3 expression (upper
right bar graph in Fig. 6D). However, the siRNA failed to downregulate
STAT3 phosphorylation at Tyr-705 (lower right bar graph in Fig. 6D)
and Ser-727 (quantitative data not shown) when normalized to total
STAT3. Although the STAT3 siRNA at best partially reduced the cellular
contents of phosphor-STAT3 at Tyr-705 (lower left bar graph in Fig. 6D)
and Ser-727 (quantitative data not shown) when normalized to β-actin,
it still suppressed, albeit partially, the expression of OSM-induced Mcl-1
(Fig. 6E) and OSM-dependent neuroprotection against 3-NP toxicity
based on Hoechst staining (Fig. 6F) and immunocytochemistry (Fig. 6G).3.7. STAT1 participates in OSM-mediated Mcl-1 induction
and neuroprotection
In addition to STAT3 phosphorylation, we also examined the effects
of OSMon the phosphorylation status of STAT1,which is another typical
transcription factor downstream of JAK. As shown in Fig. 7A, short-term
(0–60 min) treatment of OSM time-dependently increased the extents
of STAT1 phosphorylation at Tyr-701, reaching approximately 10 folds
at 15 min (bar graph); however, long-term (0–24 h) incubation of
OSM failed to stimulate Tyr-701 phosphorylation of STAT1, unlike
those observed for STAT3 at Tyr-705 and Ser-727 (Fig. 5B). STAT1 phos-
phorylation at Tyr-701 induced by 15-min exposure of OSMwas in part
suppressed by AG490 at both 200 μM and 250 μM, but not by
PD98059 at 150 μM (Fig. 7B). However, ruxolitinib at 0.5 μM exerted a
much stronger effect in abolishing OSM-mediated STAT1 phosphoryla-
tion at Tyr-701, leading to complete inhibition (Fig. 7C) thatwas similar
to those results observed for STAT3 at Tyr-705 (Fig. 5E). These ﬁndings
indicated that JAK1 and JAK2, but not ERK1/2, participate in STAT1
phosphorylation at Tyr-701 induced by OSM (Fig. 7B, C).
To explore the potential involvement of STAT1 in OSM-
dependent Mcl-1 induction and neuroprotection, pharmacological
studies employing its selective inhibitor were conducted. S14-95 isical cultures were exposed to 100 ng/ml OSM for indicated times (short-term: 0–60 min;
ve analyses of the signal intensities on the immunoblots of short-term OSM exposure (0–
red with control. (B) Cortical cultures were exposed to 100 ng/ml OSM with or without
STAT1 at Tyr-701 and total STAT1. Representative blots from 2 independent experiments
hed by AG490, but not by PD98059. (C) Cortical cultures were exposed to 100 ng/ml OSM
and total STAT1. Representative blots from 3 independent experiments using 3 different
sphorylation at Tyr-701. (D) Cortical cultures were exposed to 100 ng/ml OSM with
detection of Mcl-1. Mean ± S.E.M. from N= 3. * and # denote P b 0.05. The “ns” denotes
μM S14-95 or methanol for 24 h; this was followed by exposure to 2.5 mM 3-NP or empty
ents of cell survival. Mean ± S.E.M. from N= 3. *, #, and § all denote P b 0.05. In (F), im-
orphology of mature neurons and astrocytes. MAP-2 (red) and GFAP (green) served as
m. Note that OSM preconditioning rescued cortical neurons from 3-NP-mediated neurite
2320 S.-H. Chang et al. / Biochimica et Biophysica Acta 1853 (2015) 2306–2325a potent inhibitor derived from Penicillium that can functionally inhibit
STAT1α [42,43]. Results shown in Fig. 7D indicated that S14-95 at
20 μM [42,43] fully suppressed OSM-induced Mcl-1 expression downto the basal level. In addition, S14-95 at this dosage in part abolished
the protective effect of OSM against 3-NP based on Hoechst staining
(Fig. 7E) and immunocytochemistry (Fig. 7F).
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and neuroprotection
Previous studies have shown that CREB is implicated in IL-3 activa-
tion of Mcl-1 expression [44]. More importantly, we also identiﬁed po-
tential binding sites of CREB on the promoter region of ratMcl-1 gene
(Fig. 6A). Therefore, possible participation of CREB on the OSM effects
was also investigated. We found that OSM transiently increased the
extents of CREB phosphorylation at Ser-133, reaching the maximal
extent at 2-4 h and declined thereafter (Fig. 8A). PD98059 fully sup-
pressed OSM-dependent CREB phosphorylation back to the control
level (Fig. 8B), indicating that ERK1/2 acts upstream of CREB phosphor-
ylation induced byOSM. Indeed, PD98059 also decreased the basal level
of CREB phosphorylation even in the absence of OSM stimulation
(Fig. 8B). KG501 is a small-molecule antagonist capable of inhibiting
CREB pathway through the interference of CREB-CBP (CREB-binding
protein) interaction to attenuate target gene induction triggered by
cAMP [45]. We found that KG501 at 10 μM completely abolished
OSM-induced Mcl-1 expression; at this dosage KG501 also showed the
tendency of attenuating the expression of the endogenous Mcl-1, but
statistical signiﬁcance was not achieved (Fig. 8C). Consistently, KG501
abolished the protective effect of OSM against 3-NP in rat cortical neu-
rons based on Hoechst staining (Fig. 8D) and immunocytochemistry
(Fig. 8E).
3.9. Roles of Mcl-1 in OSM-dependent enhancement of mitochondrial
respiratory functions
We have revealed a novel and complex signaling cascade of OSM-
dependent Mcl-1 induction and neuroprotection against 3-NP, which
is a complex II inhibitor known to compromise the mitochondrial func-
tion, in cultured cortical neurons. However, the potential impacts of
OSM preconditioning and subsequent induction of Mcl-1 on mitochon-
drial bioenergetics remain undeﬁned. The capacity of mitochondrial
respiration can be measured by the changes of oxygen consumption
rate (OCR) triggered by the sequential addition of oligomycin, FCCP,
and antimycin A. These parameters including basal respiration, ATPpro-
duction, proton leak, maximal respiration rate, spare respiratory capac-
ity, and non-mitochondrial respiration may thus serve as functional
indices for the status of mitochondrial bioenergetics in cultured
cells [46]. Therefore, to address the issues of OSM effects on mito-
chondrial functions, we measured the OCRs in the cortical neurons
subjected to various experimental manipulations. Fig. 9A demon-
strates a representative result showing the real-time detection of
OCR following addition of each mitochondrial inhibitor. The basal
OCR of the mitochondrial respiration was detected before the injec-
tion of oligomycin. We found that the OCRs of basal respiration
were signiﬁcantly higher in OSM-treated cultures as compared to
those in the control cultures (Fig. 9B). To determine themaximal res-
piration rate a cell can sustain, the uncoupler FCCP was injected fol-
lowing addition of oligomycin. Results indicated that the maximal
respiration rate of OSM-treated cultures were signiﬁcantly higher
than the control cultures (Fig. 9C). The spare respiratory capacity is
a potential diagnostic index of the bioenergetics for neurons under
environmental stress [46,47]. Our results indicated that OSM consid-
erably enhanced the spare respiratory capacity in primary cortical
cultures (Fig. 9D). Consistently, the extents of ATP production wereFig. 8. Roles of CREB in the OSM-dependentMcl-1 expression and neuroprotection. (A) Rat cortica
CREB at Ser-133 and total CREB. Mean ± S.E.M. from N= 3. * denotes P b 0.05 compared with c
PD98059 for 2 h before detection of phosphor-CREB at Ser-133 and total CREB. Mean ± S.E.M. fr
were exposed to 100 ng/ml OSM with or without 10 μM KG501 for 24 h before detection of Mc
(D, E) Rat cortical cultures were exposed to 100 ng/ml OSM with or without 10 μM KG501 for 24
subject to Hoechst staining to determine the extents of cell survival. Mean± S.E.M. from N=3. *
binedwith Hoechst staining (blue) was conducted to observe themorphology of mature neurons a
mature neuronal dendrites and astrocytes. Scale bar= 20 μm. Note that OSM preconditioning resc
reversed this OSM-dependent neuroprotective effects.also higher in OSM-treated cultures (Fig. 9E) while no signiﬁcant dif-
ference in non-mitochondrial respiration was detected between the
two groups (Fig. 9F). Together, results shown in Fig. 9A-F strongly
support the contention that OSM pretreatment may enhance mito-
chondrial bioenergetics in primary cortical neurons. However,
whether this OSM effects involve induction of Mcl-1 was unknown.
To answer this question, Mcl-1 siRNA was transfected into cortical
cultures to knock down its expression. Results indicated that OSM-
induced increases in spare respiratory capacity (Fig. 9G) and ATP
production (Fig. 9H) were both suppressed by Mcl-1 siRNA, but not
the scrambled negative control siRNA. Indeed, Mcl-1 siRNA alone at-
tenuated endogenous spare respiratory capacity (Fig. 9G), but not
the ATP production despite this tendency (Fig. 9H). Taken together,
results shown in Fig. 9 suggest that OSM enhances mitochondrial
bioenergetics in cultured cortical neurons in vitro via the induction
of Mcl-1, at least in part.
4. Discussion
While it was initially puriﬁed and characterized based on the anti-
proliferative activity in human melanoma cell line in vitro [48], OSM
has now been proposed to play important roles in the CNS [1,2]. These
include suppressing proliferation of the neural precursor cells (NPCs)
in subventricular zones of adult brains [49] and supporting normal de-
velopment of nociceptive neurons in dorsal root ganglia [50]. Apart
from its functions in the development of nervous systems, potential
neuroprotective effects of OSM have been noted. For example, OSM is
a powerful protective cytokine that neutralizes excitotoxic injuries,
both in vitro and in vivo, via inhibiting NMDA-mediated increase in
free intracellular calcium ions and selectively reducing neuronal expres-
sion of the NR2C subunit of NMDA receptor [18]. Further, OSM protec-
tion of cultured neurons against glutamate-induced excitotoxicity
requires neuronal adenosine A1 receptor [19]. In another study, OSM
protects primary cortical neurons derived from embryonic mice against
the deprivation of B27, a vital supplement for growth and differentia-
tion of primary neurons; however, detailed mechanisms were not re-
ported in that study [51]. In this work, we delineated a novel and
complex signal transduction pathway involving JAK1, JAK2, ERK1/2,
STAT1, STAT3, and CREB, which together lead to Mcl-1 induction and
3-NP resistance as a result of OSM preconditioning; furthermore,
OSM-induced Mcl-1 contributes to 3-NP resistance in part via enhance-
ment of mitochondrial respiration and ATP production (Fig. 10).
In current study, pretreatment of cortical cultures with OSM at
100 ng/ml for 24 h showed optimal protective efﬁcacy against 3-NP
neurotoxicity based on Hoechst staining (Fig. 1A, B) and immunocyto-
chemical staining with neuronal marker MAP-2 (Fig. 1D). OSM under
the same experimental conditions also signiﬁcantly, albeit partially,
protected cortical cultures against neurotoxicity mediated by Aβ25-35
(Supplementary Fig. 1). In the experimental model of B27 deprivation,
the protective efﬁcacy was observed in primary mouse cortical neurons
treated with OSM at 500 ng/ml, but not at 50 or 5 ng/ml, for 72 h in a
cotreatment paradigm; further, incubation with OSM at 50 ng/ml for
72 h also enhanced neurite outgrowth [51]. Also in mouse cortical neu-
rons, preconditioning with 1 ng/ml OSM for 24 h in part attenuated
glutamate-induced excitotoxicity [19]. While the rationales underlying
these different neuroprotective dosages of OSM among the previous
studies and our own work are not clear yet, the discrepancy may bel cultures were exposed to 100 ng/ml OSM for indicated times before detection of phosphor-
ontrol culture. (B) Cortical cultures were exposed to 100 ng/ml OSMwith or without 50 μM
om N= 3. * and # denote P b 0.05. The “ns” denotes “not signiﬁcant”. (C) Cortical cultures
l-1. Mean ± S.E.M. from N= 3. * and # denote P b 0.05. The “ns” denotes “not signiﬁcant”.
h; this was followed by challenge with 2.5 mM 3-NP for additional 24 h. In (D), cells were
and § denote P b 0.05. The “ns” denotes “not signiﬁcant”. In (E), immunocytochemistry com-
nd astrocytes. MAP-2 (red) and GFAP (green) were used as the respective proteinmarker for
ued cortical neurons from 3-NP-mediated neurite fragmentation, whereas KG-501markedly
2322 S.-H. Chang et al. / Biochimica et Biophysica Acta 1853 (2015) 2306–2325attributed to several factors including differences in cell types, treat-
ment times, cell survival assays, and selection of experimental para-
digms such as pretreatment or cotreatment. Despite distinct
underlying mechanisms in different models, all these ﬁndings point to
the neuroprotective potential of OSM in the CNS.
The longer preconditioning time required for optimal protective
effects of OSM observed in this work is also interesting. Previously
we have reported that primary cortical cultures pretreated with
brain-derived neurotrophic factor (BDNF) for 8 h are more resistant
to neurotoxicity caused by subsequent 3-NP exposure [32]. In the
present study, however, the optimal preconditioning time for OSM
was observed at 24 h (Fig. 1B), substantially longer as compared to
BDNF preconditioning that takes only 8 h to achieve the maximal
protective effect [32]. In another two studies, OSM pretreatment
for 24 h was also the most efﬁcacious condition counteracting
excitotoxicity induced by NMDA [18] and glutamate [19], consistent
with our ﬁndings (Fig. 1B). Two possible reasons may be considered.
First, although heightened expression of the key protective factor
Mcl-1 was observed as early as 2 h after OSM exposure, it reached
higher levels at 24 h (Fig. 2B). Second, we found that total STAT3 ex-
pression was also increased after 16–24 h exposure to OSM (Fig. 5 F)
with sustained STAT3 phosphorylation at Tyr-705 and Ser-727 until
24 h (Fig. 5B). Indeed, similar OSM effects in stimulating STAT3 ex-
pression and continued STAT3 phosphorylation were observed
in vivo in the retina via intravitreal injection with OSM. In that
report, apart from STAT3 phosphorylation at Tyr-705 that was
prominent as early as 30 min and lasted for 48 h following adminis-
tration of OSM, heightened expression of STAT3 was also detected at
12–48 h post-injection [52]. Thus, OSM preconditioning may stimu-
late continued STAT3 activation via at least two distinct mecha-
nisms, namely sustained phosphorylation of STAT3 at Tyr-705/Ser-727
as well as increased expression of total STAT3 proteins, thereby together
contributing to the maintenance of higher levels of Mcl-1 with resultant
neuroprotective effects against 3-NP toxicity. Interestingly, OSM also ap-
peared to increase the cellular contents of STAT1 proteins after longer ex-
posure for 8–24 h (Fig. 7A). However, it is less likely that heightened
STAT1 expression contributed to the OSM-dependent long-term induc-
tion of Mcl-1. This is because, in our paradigm, OSM failed to induce
sustained phosphorylation of STAT1 at Tyr-701 (Fig. 7A).
In addition to distinct roles of various STAT proteins in mediating
OSM-dependentMcl-1 induction, various JAK proteins also play a differ-
ential role. AG490 is known to inhibit both JAK2 and JAK3 but not JAK1,
whereas ruxolitinib may suppress both JAK1 and JAK2 while sparing
JAK3 [53]. In current study, we found that ruxolitinib completely
abolished OSM-mediated STAT3 phosphorylation at Tyr-705 (Fig. 5E),
STAT1 phosphorylation at Tyr-701 (Fig. 7C), and Mcl-1 induction
(Fig. 4E). However, AG490 at best partially inhibited these OSM effects
(Figs. 4D, 5D, 7B). Moreover, we found that the maximal extent of
JAK1 phosphorylation stimulated by OSM was markedly greater than
that of JAK2 phosphorylation (25 folds for JAK1 in Fig. 4B versus 1.5
folds for JAK2 in Fig. 4A). Therefore, these results appear to suggest
participation of both JAK1 and JAK2, in which JAK1 may play a more
dominant role in the observed OSM effects.
Phosphorylation of STAT3 at distinct amino acid residues by speciﬁc
kinases plays a critical role in transducing its downstream signaling cas-
cades. For example, STAT3 phosphorylation at Tyr-705 is required for its
biological activation, whereas phosphorylation at Ser-727 may further
enhance its activity [4,5]. In general, STAT3 phosphorylation at Tyr-
705 is JAK-dependent and Ser-727 phosphorylation of STAT3 is mainly
regulated by MAPKs or Akt [4,5,54]. In addition, studies have revealed
that both phosphorylated sites of STAT3 are required for its activity in
rat hippocampal neurons in response to transient depolarization, in
which STAT3 phosphorylation at Tyr-705 depends on JAK while Ser-
727 is mediated by Akt [55]. In this work, we found that JAK1 (Fig. 5E)
and JAK2 (Fig. 5D)were responsible for OSM-induced STAT3 phosphor-
ylation at Tyr-705, whereas ERK1/2 mediated Ser-727 phosphorylation(Fig. 5D). ERK1/2 also participated in the phosphorylation of CREB
(Fig. 8B). Akt, however, may not be involved in OSM-induced STAT3
phosphorylation at Ser-727 because OSM failed to affect Akt phosphor-
ylation in cortical cultures (Supplementary Fig. 3A). Similarly, JNK is not
important for the observed OSM effects because its phosphorylation
was unaffected by OSM, at least within the ﬁrst 60min (Supplementary
Fig. 3B), and its inhibitor SP600125 was not effective in attenuating
OSM-induced Mcl-1 expression (Supplementary Fig. 3C).
Although STAT3 inhibitor stattic completely inhibited OSM-induced
Mcl-1 expression (Fig. 6C), we found that STAT3 siRNA only partially
suppressed OSM-induced Mcl-1 expression (Fig. 6E) and neuroprotec-
tion (Fig. 6F, G). At present, our ﬁndings suggest that STAT3 is necessary
for OSM-mediatedMcl-1 induction and neuroprotection.Whether acti-
vation of STAT3 alone is sufﬁcient for the Mcl-1 induction and 3-NP re-
sistance requires further investigation. Given the involvements of
STAT1 (Fig. 7) and CREB (Fig. 8) in addition to STAT3 (Figs. 5 and 6), it
appears reasonable to observe only partial abolishment of OSM-
mediated neuroprotection when the corresponding inhibitor against
STAT3, STAT1, or CREBwas individually applied to cortical cultures dur-
ing the preconditioning phase. The interplay between STAT1, STAT3,
and CREB as well as other possible factors in OSM-induced Mcl-1
expression and neuroprotection is still unclear. Furthermore, while
the STAT3 siRNA completely abrogated OSM-induced expression of
STAT3 proteins back to basal level as compared to the control cultures
(Fig. 6D), the presence of the phosphorylated, and hence activated,
STAT3was still evident after OSM treatment. Indeed, when normalizing
the cellular level of phosphor-STAT3 at Tyr-705 to that of total STAT3, no
signiﬁcant difference between OSM-treated cultures with and without
STAT3 siRNA transfection was observed (Fig. 6D); similar ﬁndings with
phosphor-STAT3 at Ser-727 were observed (Fig. 6D and quantitative
data not shown). These ﬁndings indicate that, while siRNA is efﬁcacious
in attenuating STAT3 expression, it cannot completely eliminate the
presence of phosphor-STAT3 because the residual STAT3 proteins are
still subject to phosphorylation by JAK1, JAK2, and ERK1/2, which may
explain the partial inhibitory effects of STAT3 siRNA on OSM-mediated
Mcl-1 induction (Fig. 6E) and possibly neuroprotection against 3-NP
toxicity (Fig. 6F, G).
So far, the only one study revealingMcl-1 as one of the downstream
target genes inducible by OSM was based on DNA microarray, which
was conducted in osteosarcoma cells [36]. The underlying molecular
mechanismswere not characterized in that report. Mcl-1 is traditionally
known as an anti-apoptotic protein that may have neuroprotective
functions. For example, overexpression of Mcl-1 reduces the progres-
sion of age-related cochlear dysfunction and sensory cell death by sup-
pressing cochlear apoptosis at the mitochondrial level [56]. Parkin,
encoded by PARK2 that is the most frequently mutated gene in heredi-
tary Parkinson's disease, suppresses apoptosis of dopaminergic neurons
in response to oxidative stress via stabilizing Mcl-1 [57]. Using primary
cultures of cerebellar granule neurons deprived of serum and potassium
as a model system, it has been demonstrated that ubiquitination and
subsequent degradation of Mcl-1 initiate apoptosis [58]. In current
study, we showed that Mcl-1 is the critical mediator for OSM-
dependent protection against 3-NP-inducedmitochondrial dysfunction
and neuronal death. In addition to the remarkable neuroprotective ef-
fects of OSM against 3-NP, we also observed that preconditioning with
100 ng/ml OSM for 24 hmodestly conferred neuronal resistance against
Aβ25-35 toxicity (Supplementary Fig. 1A). It should be noted that we
did not optimize the protective conditions of OSM for Aβ25-35 as this
is beyond the scope of the present study. Nevertheless, this partial pro-
tective effect of OSM against Aβ25-35, unlike 3-NP, does not involve
Mcl-1 (Supplementary Fig. 1B). These results indicated that OSM may
trigger diversiﬁed defense mechanisms and, given the different patho-
logical mechanisms of 3-NP [59–61] and Aβ25-35 [35,62,63], it is possi-
ble that Mcl-1 may not be the only downstream molecule mediating
OSM-dependent neuroprotection. Additional components contributing
to the observed OSM effects await identiﬁcation.
Fig. 9. Effects of OSMonmitochondrial respiratory function and the involvement ofMcl-1. Cultureswere incubated in 100 ng/ml OSM for 24h followedby replacement of fresh neurobasal
medium supplementedwith B27 for additional 4 h. One representativemeasurement of OCR is shown in (A). Various bioenergenic indices for mitochondrial function, including basal res-
piration (B), maximal respiration (C), spare respiratory capacity (D), ATP production (E), and non-mitochondrial respiration (F; Non-mito respiration) were conducted and calculated as
described inMaterials and methods. Mean ± S.E.M. from N=10–12 out of 4 different cultures. * denotes P b 0.05. The “ns” denotes “not signiﬁcant”. (G, H) The experimental conditions
were the same as described in (A–F) except that, prior to OSM pretreatment, cortical cultures were transfected with 1 μMMcl-1 siRNA or sc siRNA for 72 h during DIV4-7. The effects of
OSM andMcl-1 knockdown on spare respiratory capacity (G) and ATP production (H) are shown.Mean± S.E.M. fromN=5–7 out of 3 different cultures. * and # denote P b 0.05. The “ns”
denotes “not signiﬁcant”.
2323S.-H. Chang et al. / Biochimica et Biophysica Acta 1853 (2015) 2306–2325In our paradigm, OSM speciﬁcally induced expression ofMcl-1with-
out affecting expression of the anti-apoptotic Bcl-2 (Supplementary
Fig. 2A) and Bcl-xL (Supplementary Fig. 2B). Neither did OSMmodulate
the extents of cleaved caspase-3 associated with 3-NP exposure
(Supplementary Fig. 2C), thus excluding the caspase-dependentapoptotic pathway as a prime target of Mcl-1. These ﬁndings led to
the important question of how OSM and its downstream mediator
Mcl-1 protect cortical neurons from 3-NP. Given the inhibitory effects
of 3-NP on the mitochondrial complex II with resultant ATP depletion,
it appeared reasonable to investigate the potential impact of OSM on
Fig. 10. A diagram showing the proposed signal transduction pathways underlying OSM-
dependent induction of Mcl-1 and its neuroprotective effects against mitochondrial inhi-
bition induced by 3-NP in cortical cultures.
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preconditioning signiﬁcantly enhanced basal respiration rate, maximal
respiration, spare respiration capacity, and ATP production without af-
fecting non-mitochondrial respiration (Fig. 9A-F). Several studies have
demonstrated that the neuroprotective efﬁcacy of various reagents
may rely on their capabilities of restoring mitochondrial bioenergetics.
For example, in PC12 cells challenged with 3-NP, treatment with
Psoralea corylifolia Linn seed extracts signiﬁcantly stimulatedmitochon-
drial respiration and increased bioenergetic reserve capacity, thereby
leading to restoration of ATP levels and attenuation of cell death [30].
Pretreatment of magnesium sulfate also protects a selective population
of primary cortical neurons against glutamate-induced loss of spare re-
spiratory capacity [64]. Indeed, spare respiratory capacity, rather than
oxidative stress, regulates glutamate excitotoxicity after partial respira-
tory inhibition of mitochondrial complex I with rotenone in rat cerebel-
lar granule neurons [47]. These previous and our own studies indicate
that selected protective reagents may rescue neurons from mitochon-
drial dysfunction via restoration of bioenergetics without affecting
caspase-dependent apoptotic mechanisms. Intriguingly, to our best
knowledge this is the ﬁrst study reporting the capability of OSM, a cyto-
kine belonging to the IL-6 family, in boosting mitochondrial respiration
rate with increased ATP production. This effect is speciﬁc to OSM as
preconditioning of cortical neurons with BDNF did not enhance ATP
production (Wu and Yang, unpublished observations).
Downstream of OSM, siRNA-mediated knockdown experiments
conﬁrmed thatMcl-1 in part contributed to the increases in spare respi-
ratory capacity (Fig. 9G) andATP production (Fig. 9H).While the under-
lyingmechanisms remain obscure, one recent study reported thatMcl-1
can be imported into themitochondrialmatrix to facilitate normalmito-
chondrial fusion, ATP production, respiration, and maintenance of
oligomeric ATP synthase; further, deletion of Mcl-1 decreases bothbasal and maximal OCRs as well as cellular ATP contents in murine em-
bryonic ﬁbroblasts [11]. These results are consistent with our own ﬁnd-
ings that Mcl-1 induced by OSM contributes to enhancement of
mitochondrial bioenergetics. In addition to Mcl-1, OSM also activates
transcription of long-chain acyl-coenzymeA (CoA) synthetase isoforms
3 and 5 (ACSL3, ACSL5) in the livers of hamsters, which are associated
with decreased triglyceride accumulation and increased fatty acid
β-oxidation [65].While the extent of ATP productionwas notmeasured
in that study, it is tempting to speculate that enhanced β-oxidation of
fatty acids likely results in increased ATP synthesis. Finally, other mech-
anisms not directly related to ATPproduction should also be considered.
For example, since deletion of Mcl-1 in post-mitotic cortical neurons
may increase autophagic responses [66,67], possible involvement of
autophagy in mediating OSM- and Mcl-1-dependent neuroprotective
effects remains to be a possibility and awaits further investigation.
In conclusion, we have demonstrated the neuroprotective actions of
OSM preconditioning against mitochondrial inhibition in response to
3-NP exposure.We also revealed a novel and complex signal cascade in-
volving JAK1, JAK2, ERK1/2, STAT1, STAT3, and CREB aswell as their tar-
get Mcl-1 that together contribute to OSM-dependent neuroprotective
effects against mitochondrial dysfunction commonly associated with
neurodegeneration. Furthermore, we found that OSM-dependent Mcl-
1 induction in part contributes to the enhancements of mitochondrial
bioenergetics in primary cortical cultures. Administration of OSM to
animal models mimicking neurodegenerative disorders for the studies
of its therapeutic potential warrants further investigation.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2015.05.014.
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